CHI-California Healthcare Institute Board Elects New Members, Chairman

LA JOLLA, Calif.--(BUSINESS WIRE)-- CHI-California Healthcare Institute announced today that Terry Hermiston, Ph.D., vice president of the U.S. Biologics Research unit within Bayer HealthCare’s worldwide pharmaceutical research organization, and Naomi Kelman, president of LifeScan North America, have been elected to the CHI board of directors. The board of directors also elected Carl Hull, president and chief executive officer of Gen-Probe Inc., to be its chairman for 2011-2012. CHI is a non-profit public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.

“We are pleased to welcome Bayer and LifeScan to our board,” said David Gollaher, Ph.D., CHI president and CEO. “Naomi’s leadership will be crucial to CHI as it navigates important policy and healthcare issues such as childhood diabetes, an epidemic in California. Additionally, Terry brings a wealth of knowledge to CHI as the head of Bayer’s new U.S. Innovation Center in Mission Bay, a key investment to driving new science and medical innovations in California.”

“Carl, who has been a dedicated board member since July 2009, has shown great leadership and with his passion for public policy and his deep background in diagnostics, will help guide CHI’s activities in 2011.”

Hermiston serves as vice president of the U.S. Biologics Research unit within Bayer HealthCare’s worldwide pharmaceutical research organization. He also manages the operation of Bayer’s U.S. Innovation Center. Prior to joining Bayer HealthCare in 2007, Hermiston was a principal scientist and scientific director for the Global Gene Therapy Research and Gene Technology Departments for Berlex Biosciences and its German parent company, Schering AG. He started his career in the biotechnology industry at Onyx Pharmaceuticals as head of its oncolytic virus research program following completion of a National Institutes of Health (NIH) fellowship in microbiology and immunology at the St. Louis University School of Medicine.

With a biotechnology career spanning nearly two decades, Hermiston has published more than 50 research papers, holds 10 patents and has additional patents pending. He has served on various National Cancer Institute (NCI) and NIH committees and continues to actively participate as an editor and ad hoc reviewer for several journals including Current Opinion in Molecular Therapeutics and the soon-to-be-launched Biopharmaceuticals.

Kelman has served as president of LifeScan North America, part of the Johnson & Johnson Diabetes franchise, since July 2009. She oversees the OneTouch business, a U.S. category leader of blood glucose monitoring systems for people with diabetes. Prior to joining LifeScan, Kelman held several leadership positions within the Consumer and Medical Device and Diagnostic sectors at J&J. As president of J&J Vision Care for the Americas, she was responsible for Acuvue brand contact lenses, where she accelerated category and share gains, doubling the Acuvue business in just five years. In the consumer sector, as part of J&J’s personal products company, Kelman also oversaw marketing in the feminine hygiene, oral health and women’s health categories.

Before joining J&J, Kelman spent several years in marketing at Bristol-Myers Squibb (BMS) in the Clairol division. She held brand management marketing positions of increasing responsibility in the U.S. before moving to London in 1994 to oversee the global expansion of some of the company’s biggest consumer brands into the European, Middle Eastern and African markets. In 1998, Kelman was appointed managing director of Matrix Essentials business for Europe and then vice president of marketing for the company’s worldwide Matrix Essentials business. Prior to her work at BMS, Kelman was in finance at American Express.

Hull joined Gen-Probe in 2007 as executive vice president and chief operating officer. He was promoted to president in 2008, and chief executive officer in 2009. He previously served as vice president and general manager of the SDS/Arrays business unit of Applied Biosystems, which develops and sells genomic research systems and reagents. Prior to joining Applied Biosystems, Hull held a number of positions with Applied Imaging Corp., which makes automated imaging and imaging analysis systems, most recently serving as its CEO. He received a bachelor’s degree in political science and international relations from the Johns Hopkins University and a master’s in business administration from the University of Chicago.

About CHI

CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. Follow us on Twitter @calhealthcare and Facebook.

Editorial note: photos available upon request.



CONTACT:

CHI-California Healthcare Institute
Nicole Beckstrand, 858-456-8881
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.